MX2020002596A - Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. - Google Patents

Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.

Info

Publication number
MX2020002596A
MX2020002596A MX2020002596A MX2020002596A MX2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A
Authority
MX
Mexico
Prior art keywords
multimeric
lymphocyte
methods
modulating
modulating polypeptides
Prior art date
Application number
MX2020002596A
Other languages
English (en)
Spanish (es)
Inventor
Ronald D Ill Seidel
Rodolfo J Chaparro
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of MX2020002596A publication Critical patent/MX2020002596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
MX2020002596A 2017-09-07 2018-09-06 Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. MX2020002596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
MX2020002596A true MX2020002596A (es) 2020-07-20

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002596A MX2020002596A (es) 2017-09-07 2018-09-06 Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.

Country Status (13)

Country Link
US (4) US20200148744A1 (enExample)
EP (1) EP3678691A4 (enExample)
JP (1) JP2020533273A (enExample)
KR (1) KR20200040860A (enExample)
CN (1) CN111050793A (enExample)
AU (1) AU2018328280B2 (enExample)
BR (1) BR112020004535A2 (enExample)
CA (1) CA3070484A1 (enExample)
EA (1) EA202090471A1 (enExample)
IL (2) IL297361B2 (enExample)
MX (1) MX2020002596A (enExample)
TW (1) TWI918592B (enExample)
WO (1) WO2019051091A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808552XA (en) * 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TWI855242B (zh) * 2020-03-18 2024-09-11 南韓商Ｇｉ醫諾微新股份有限公司 包含含有il-2蛋白與cd80蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022015880A2 (en) * 2020-07-14 2022-01-20 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
JP2025508958A (ja) * 2022-03-01 2025-04-10 クロスリンク セラピューティクス インク． 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト
EP4709743A1 (en) * 2023-05-11 2026-03-18 Immudex ApS Mhc class i molecules
WO2026125765A1 (en) 2024-12-13 2026-06-18 Immunoscape Pte. Ltd. Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
PL377028A1 (pl) * 2002-03-26 2006-01-23 Immunex Corporation Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
AU2015209540B2 (en) * 2014-01-21 2021-05-13 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive T-cell immunomonitoring
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン ｓｙｎＴａｃポリペプチド及びその使用
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano

Also Published As

Publication number Publication date
US20200148744A1 (en) 2020-05-14
TW201920248A (zh) 2019-06-01
CA3070484A1 (en) 2019-03-14
JP2020533273A (ja) 2020-11-19
WO2019051091A1 (en) 2019-03-14
EP3678691A4 (en) 2021-06-09
AU2018328280A1 (en) 2020-02-13
IL297361B2 (en) 2024-07-01
US20240025964A1 (en) 2024-01-25
CN111050793A (zh) 2020-04-21
EP3678691A1 (en) 2020-07-15
IL272085B (en) 2022-11-01
IL297361B1 (en) 2024-03-01
EA202090471A1 (ru) 2020-06-10
IL272085B2 (en) 2023-03-01
IL272085A (en) 2020-03-31
US20220119483A1 (en) 2022-04-21
IL297361A (en) 2022-12-01
TWI918592B (zh) 2026-03-21
AU2018328280B2 (en) 2025-02-20
US20250002556A1 (en) 2025-01-02
BR112020004535A2 (pt) 2020-09-08
KR20200040860A (ko) 2020-04-20

Similar Documents

Publication Publication Date Title
MX2021014476A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
MX2021007287A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
EA202090471A1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
BR112019012964A2 (pt) polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos
MX2022003367A (es) Polipeptidos moduladores de linfocitos t y metodos de uso de estos.
MX2021007479A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
CL2021000738A1 (es) Proteínas de fijación a sirpa y métodos de uso de estas
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
BR112018073606A2 (pt) polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
MX382518B (es) Antigenos de citomegalovirus y su uso.
CO2020012584A2 (es) Suministro intracelular de biomoléculas para modificar respuestas inmunes
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
EP4431109A3 (en) Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX389823B (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MX372658B (es) Anticuerpos anti-cd3 y metodos de uso.
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
MX2021005540A (es) Peptidos inmunogenicos con motivos de oxidorreductasa mejorados.
IL290910A (en) Modified tff2 polypeptides containing compositions and methods of use thereof
BR112019002127A2 (pt) proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
IL281972A (en) Methods and compositions for modulation of tau proteins
WO2014179491A3 (en) MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-η
EP4450083A3 (en) H3.3 ctl peptides and uses thereof